Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) has announced updated efficacy and safety data for its candidate bladder cancer therapy durvalumab.
MedImmune, the company’s biologics R&D arm, presented results from a Phase I/II study that showed an objective response rate (ORR) of 20.4% in all evaluable patients.
David Berman, head of oncology, innovative medicines, said: “The durable responses observed in this larger data set confirm the promising efficacy we’ve already seen for durvalumab in patients with advanced bladder cancer.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze